Stage II Pancreatic Cancer AJCC v8 (DBCOND0116519)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04550494	Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations	Talazoparib	treatment	2	recruiting
NCT06626256	STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma	Aldesleukin Cyclophosphamide Fludarabine	treatment	1	not_yet_recruiting
NCT05053971	Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas	Entinostat	treatment	1 / 2	recruiting
NCT05411094	Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer	Durvalumab Olaparib	treatment	1	recruiting
NCT06423326	Gemcitabine, Cisplatin and Nab-Paclitaxel As Neoadjuvant Treatment for Patients with Resectable or Borderline Resectable Pancreatic Cancer	Albumin human Chloride ion Cisplatin Gemcitabine Paclitaxel Platinum	treatment	2	recruiting
NCT04005690	Targeted Pathway Inhibition in Patients With Pancreatic Cancer	Azenosertib Cobimetinib Olaparib Onvansertib Saruparib Tremelimumab	treatment	0	recruiting
NCT06398587	Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma	Albumin human Gemcitabine Onvansertib Paclitaxel	treatment	2	withdrawn
NCT03784677	A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors	Calcium SOR-C13	treatment	1	completed
NCT04887805	Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer	Lenvatinib Pembrolizumab	treatment	2	recruiting
NCT04106856	Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)	Losartan	treatment	1	recruiting
NCT04616534	Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	Elimusertib Gemcitabine	treatment	1	active_not_recruiting
NCT03816358	Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer	Anetumab ravtansine Gemcitabine Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT03033225	Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study	Verteporfin	treatment	2	completed
NCT04111172	A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma	No drug interventions	treatment	2	suspended
NCT03291938	IACS-010759 in Advanced Cancers	No drug interventions	treatment	1	completed
NCT05911243	Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer	No drug interventions	supportive_care	Not Available	recruiting
NCT04821284	Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer	Albumin human Calcium Camptothecin Fluorouracil Gemcitabine Irinotecan Leucovorin Levoleucovorin Oxaliplatin Paclitaxel Platinum	treatment	1 / 2	recruiting
NCT04449679	Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study	No drug interventions	supportive_care	Not Available	completed
NCT06381154	Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer	Fluorouracil Irinotecan Leucovorin Oxaliplatin Pembrolizumab Verteporfin	treatment	2	not_yet_recruiting
NCT03925428	Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas	Entinostat Molibresib	treatment	1	withdrawn
NCT02983578	Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer	Danvatirsen Durvalumab	treatment	2	active_not_recruiting
NCT05733000	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	Devimistat Fluorouracil Gemcitabine Hydroxychloroquine Lipoic acid	treatment	2	recruiting
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	Abemaciclib Abiraterone Afatinib Albumin human Avobenzone Bevacizumab Bicalutamide Bortezomib Bortezomib D-mannitol Cabazitaxel Cabozantinib Capecitabine Carboplatin Celecoxib Cobimetinib Copanlisib Dabrafenib Dacomitinib Darolutamide Dasatinib Daunorubicin Doxorubicin Durvalumab Enasidenib Entrectinib Enzalutamide Erlotinib Everolimus Fluorouracil Idelalisib Imatinib Ipilimumab Lenvatinib Leucovorin Lorlatinib Losartan Neratinib Nivolumab Octinoxate Olaparib Oxaliplatin Paclitaxel Palbociclib Panobinostat Pembrolizumab Pertuzumab Ponatinib Regorafenib Ruxolitinib Sirolimus Sorafenib Sunitinib Trametinib Trastuzumab emtansine Tretinoin Vemurafenib Venetoclax Vismodegib Vorinostat	treatment	1	terminated
NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	Albumin human Alectinib Alpelisib Anastrozole Atezolizumab Bevacizumab Capecitabine Carboplatin Cobimetinib Entrectinib Eribulin Fulvestrant Hyaluronidase (human recombinant) Irinotecan Letrozole Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Trastuzumab Trastuzumab emtansine Vemurafenib Vinorelbine Vismodegib	treatment	0	withdrawn
NCT05034627	Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer	Asparaginase Escherichia coli Benzalkonium Calaspargase pegol Carbonate ion Cobimetinib	treatment	1	recruiting
NCT03432676	Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer	Epacadostat Pembrolizumab	treatment	2	withdrawn
NCT06206876	FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma	No drug interventions	treatment	1	not_yet_recruiting
NCT05055323	A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer	Pyrvinium	treatment	1	recruiting